Cargando…
Propofol Infusion Syndrome in Adults: A Clinical Update
Propofol infusion syndrome is a rare but extremely dangerous complication of propofol administration. Certain risk factors for the development of propofol infusion syndrome are described, such as appropriate propofol doses and durations of administration, carbohydrate depletion, severe illness, and...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410753/ https://www.ncbi.nlm.nih.gov/pubmed/25954513 http://dx.doi.org/10.1155/2015/260385 |
_version_ | 1782368374848749568 |
---|---|
author | Mirrakhimov, Aibek E. Voore, Prakruthi Halytskyy, Oleksandr Khan, Maliha Ali, Alaa M. |
author_facet | Mirrakhimov, Aibek E. Voore, Prakruthi Halytskyy, Oleksandr Khan, Maliha Ali, Alaa M. |
author_sort | Mirrakhimov, Aibek E. |
collection | PubMed |
description | Propofol infusion syndrome is a rare but extremely dangerous complication of propofol administration. Certain risk factors for the development of propofol infusion syndrome are described, such as appropriate propofol doses and durations of administration, carbohydrate depletion, severe illness, and concomitant administration of catecholamines and glucocorticosteroids. The pathophysiology of this condition includes impairment of mitochondrial beta-oxidation of fatty acids, disruption of the electron transport chain, and blockage of beta-adrenoreceptors and cardiac calcium channels. The disease commonly presents as an otherwise unexplained high anion gap metabolic acidosis, rhabdomyolysis, hyperkalemia, acute kidney injury, elevated liver enzymes, and cardiac dysfunction. Management of overt propofol infusion syndrome requires immediate discontinuation of propofol infusion and supportive management, including hemodialysis, hemodynamic support, and extracorporeal membrane oxygenation in refractory cases. However, we must emphasize that given the high mortality of propofol infusion syndrome, the best management is prevention. Clinicians should consider alternative sedative regimes to prolonged propofol infusions and remain within recommended maximal dose limits. |
format | Online Article Text |
id | pubmed-4410753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-44107532015-05-07 Propofol Infusion Syndrome in Adults: A Clinical Update Mirrakhimov, Aibek E. Voore, Prakruthi Halytskyy, Oleksandr Khan, Maliha Ali, Alaa M. Crit Care Res Pract Review Article Propofol infusion syndrome is a rare but extremely dangerous complication of propofol administration. Certain risk factors for the development of propofol infusion syndrome are described, such as appropriate propofol doses and durations of administration, carbohydrate depletion, severe illness, and concomitant administration of catecholamines and glucocorticosteroids. The pathophysiology of this condition includes impairment of mitochondrial beta-oxidation of fatty acids, disruption of the electron transport chain, and blockage of beta-adrenoreceptors and cardiac calcium channels. The disease commonly presents as an otherwise unexplained high anion gap metabolic acidosis, rhabdomyolysis, hyperkalemia, acute kidney injury, elevated liver enzymes, and cardiac dysfunction. Management of overt propofol infusion syndrome requires immediate discontinuation of propofol infusion and supportive management, including hemodialysis, hemodynamic support, and extracorporeal membrane oxygenation in refractory cases. However, we must emphasize that given the high mortality of propofol infusion syndrome, the best management is prevention. Clinicians should consider alternative sedative regimes to prolonged propofol infusions and remain within recommended maximal dose limits. Hindawi Publishing Corporation 2015 2015-04-12 /pmc/articles/PMC4410753/ /pubmed/25954513 http://dx.doi.org/10.1155/2015/260385 Text en Copyright © 2015 Aibek E. Mirrakhimov et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Mirrakhimov, Aibek E. Voore, Prakruthi Halytskyy, Oleksandr Khan, Maliha Ali, Alaa M. Propofol Infusion Syndrome in Adults: A Clinical Update |
title | Propofol Infusion Syndrome in Adults: A Clinical Update |
title_full | Propofol Infusion Syndrome in Adults: A Clinical Update |
title_fullStr | Propofol Infusion Syndrome in Adults: A Clinical Update |
title_full_unstemmed | Propofol Infusion Syndrome in Adults: A Clinical Update |
title_short | Propofol Infusion Syndrome in Adults: A Clinical Update |
title_sort | propofol infusion syndrome in adults: a clinical update |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410753/ https://www.ncbi.nlm.nih.gov/pubmed/25954513 http://dx.doi.org/10.1155/2015/260385 |
work_keys_str_mv | AT mirrakhimovaibeke propofolinfusionsyndromeinadultsaclinicalupdate AT vooreprakruthi propofolinfusionsyndromeinadultsaclinicalupdate AT halytskyyoleksandr propofolinfusionsyndromeinadultsaclinicalupdate AT khanmaliha propofolinfusionsyndromeinadultsaclinicalupdate AT alialaam propofolinfusionsyndromeinadultsaclinicalupdate |